1. Home
  2. CYBN vs EDF Comparison

CYBN vs EDF Comparison

Compare CYBN & EDF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • CYBN
  • EDF
  • Stock Information
  • Founded
  • CYBN 2019
  • EDF 2010
  • Country
  • CYBN Canada
  • EDF United States
  • Employees
  • CYBN N/A
  • EDF N/A
  • Industry
  • CYBN Pharmaceuticals and Biotechnology
  • EDF Investment Managers
  • Sector
  • CYBN Health Care
  • EDF Finance
  • Exchange
  • CYBN Nasdaq
  • EDF Nasdaq
  • Market Cap
  • CYBN 176.0M
  • EDF 156.6M
  • IPO Year
  • CYBN N/A
  • EDF N/A
  • Fundamental
  • Price
  • CYBN $7.11
  • EDF $5.09
  • Analyst Decision
  • CYBN Strong Buy
  • EDF
  • Analyst Count
  • CYBN 3
  • EDF 0
  • Target Price
  • CYBN $85.00
  • EDF N/A
  • AVG Volume (30 Days)
  • CYBN 351.0K
  • EDF 160.6K
  • Earning Date
  • CYBN 08-13-2025
  • EDF 01-01-0001
  • Dividend Yield
  • CYBN N/A
  • EDF 13.14%
  • EPS Growth
  • CYBN N/A
  • EDF N/A
  • EPS
  • CYBN N/A
  • EDF N/A
  • Revenue
  • CYBN N/A
  • EDF N/A
  • Revenue This Year
  • CYBN N/A
  • EDF N/A
  • Revenue Next Year
  • CYBN N/A
  • EDF N/A
  • P/E Ratio
  • CYBN N/A
  • EDF N/A
  • Revenue Growth
  • CYBN N/A
  • EDF N/A
  • 52 Week Low
  • CYBN $4.81
  • EDF $3.51
  • 52 Week High
  • CYBN $13.88
  • EDF $5.50
  • Technical
  • Relative Strength Index (RSI)
  • CYBN 45.43
  • EDF 51.64
  • Support Level
  • CYBN $6.36
  • EDF $5.06
  • Resistance Level
  • CYBN $7.75
  • EDF $5.13
  • Average True Range (ATR)
  • CYBN 0.34
  • EDF 0.04
  • MACD
  • CYBN -0.04
  • EDF -0.00
  • Stochastic Oscillator
  • CYBN 51.95
  • EDF 30.77

About CYBN Cybin Inc.

Cybin Inc is a biopharmaceutical company involved in creating safe and effective therapeutics for patients to address a multitude of mental health issues. The Company is a clinical-stage neuropsychiatric company focused on advancing therapies, delivery mechanisms, novel compounds, and protocols as potential treatments for various psychiatric and neurological conditions. The Company is developing technologies and delivery systems aimed at improving the pharmacokinetics of its proprietary molecules while retaining the therapeutic benefit. These new molecules and delivery systems are expected to be studied through clinical trials to confirm safety and efficacy.

About EDF Virtus Stone Harbor Emerging Markets Income Fund of Beneficial Interest

Virtus Stone Harbor Emerging Markets Income Fund is a closed-end management investment company. Its investment objective is to maximize total return, which consists of income from its investments and capital appreciation. The Fund normally will invest at least 80% of its net assets (plus any borrowings for investment purposes) in emerging markets securities.

Share on Social Networks: